Qiao-Yan Yi

Qiao-Yan Yi

Auto-generated profile, based on publicly available information

Qiao-Yan Yi

Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy Jinan China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
GJGuang-Bin Jiang
Guang-Bin Jiang
WZWen-Yao Zhang
Wen-Yao Zhang
MHMiao He
Miao He
Yiying GuYiying Gu
Yiying Gu
LBLan Bai
Lan Bai
FDFan Du
Fan Du

2 May 2019 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
MHMiao He
Miao He
QYQiao-Yan Yi
Qiao-Yan Yi
WZWen-Yao Zhang
Wen-Yao Zhang
LBLan Bai
Lan Bai
FDFan Du
Fan Du
PWPeng Wei
Peng Wei
In this study, we designed and synthesized three new iridium(III) complexes [Ir(ppy)2(dmdppz)](PF6) (ppy = 2-phenylpyridine) (1), [Ir(bzq)2(dmdppz)](PF6) (bzq = benzo[h]quinolone) (2) and [Ir(piq)2(dmdppz)](PF6) (piq = 1-phenylisoquinoline, dmdppz = 5,8-dimethoxylpyrido[3,2-a:2′,3′-c]phenazine) (3). All the complexes were tested for anticancer activity by the 3-(4,5-dimethylthiazole)-2,5-diphenyltetrazolium bromide (MTT) method. These complexes showed high anticancer activity against SGC-7901 cells, and the IC50 values are 4.1 ± 0.5 for 1, 0.7 ± 0.1 for 2 and 0.6 ± 0.2 μM for 3. Additionally, complex 3 can inhibit the tumor growth in xenograft nude mice in vivo with an inhibitory percentage of tumor growth of 48.21%. Morphological studies show that the cells treated with the complexes exhibit typical apoptotic morphological characteristics such as nuclear fragmentation and chromatin condensation. Quantitative analysis by flow cytometry showed that the apoptosis rate increased sharply after the cells were exposed to the complexes, and NAC (an inhibitor that inhibits the production of ROS) can inhibit the increase of the apoptosis rate. Cell cycle studies show that complex 1 can block the SGC-7901 cell cycle at the G0/G1 phase, and complexes 2 and 3 can cause cycle arrest at the S phase. All the complexes can increase the intracellular reactive oxygen species level, and reduce the mitochondrial membrane potential, which further prompts the release of cytochrome c. In addition, the complexes can damage DNA and cause disruption of the microtubule network. In conclusion, the complexes can effectively induce cancer cell apoptosis and may be potential anticancer agents for gastric cancer.

3 December 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
YSYishuo Shu
Yishuo Shu
YSYinping Shi
Yinping Shi
YYYilei Yang
Yilei Yang
ZDZhonghua Dong
Zhonghua Dong
QYQiaoyan Yi
Qiaoyan Yi
HSHai-yan Shi
Hai-yan Shi